Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-Line Treatment

Authors

  • Lisa Bilston, MD, FRCPC Division of Hematology and Hematologic Malignancies, University of Calgary
  • Kareem Jamani, MD, FRCPC Division of Hematology and Hematologic Malignancies, University of Calgary

DOI:

https://doi.org/10.58931/cht.2024.3253

Abstract

With advances in treatment for chronic myeloid leukemia (CML), the natural history of chronic phase (CP) CML has changed, with most individuals expected to live a normal life expectancy. The goal of therapy for most is to achieve a long-term deep molecular response (DMR) with the potential for medication discontinuation and treatment-free remission (TFR).1 Currently, six oral therapies have been approved for CP-CML in Canada: (1) imatinib, a first-generation tyrosine kinase inhibitor (TKI); (2) dasatinib, (3) nilotinib, and (4) bosutinib, the second-generation TKIs (2G-TKIs); (5) ponantinib, a third-generation TKI; and (6) asciminib, specifically targeting the ABL Myristoyl pocket (STAMP) inhibitor. Classically, treatment for CP-CML has consisted of front-line imatinib and switching to a 2G-TKI upon treatment resistance or intolerance. Increasingly, patients are being prescribed an upfront 2G-TKI with the goal of achieving quicker and deeper molecular remissions and a TFR.2 Challenges arise in CML when treatment with either two TKIs (imatinib + 2G-TKI) or one 2G-TKI fails, given the lack of evidence to inform clinical decision-making at this juncture. This paper aims to define TKI failure and help guide the selection of second-line treatment after failure of front-line therapy. 

Author Biographies

Lisa Bilston, MD, FRCPC, Division of Hematology and Hematologic Malignancies, University of Calgary

Dr. Lisa Bilston is currently completing residency in Hematology at the University of Calgary, where she also completed medical school and Internal Medicine training. She will be starting as a hematologist with the Central Alberta Cancer Center and Red Deer Regional Hospital. 

Kareem Jamani, MD, FRCPC, Division of Hematology and Hematologic Malignancies, University of Calgary

Dr. Kareem Jamani is a clinical assistant professor at the University of Calgary and an attending physician at the Tom Baker Cancer Centre and Alberta Blood & Marrow Transplant Program. His clinical practice comprises myeloid neoplasms, acute leukemias and allogeneic stem cell transplant. Dr. Jamani’s research interests include post-transplant toxicities, survivorship, and quality of life. 

References

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Mar 3;34(34).

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. American Journal of Hematology. 2022 Jul 6;97(9).

Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network [Internet]. 2020 Oct 1;18(10):1385–415.

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. New England Journal of Medicine. 2017 Mar 9;376(10):917–27.

Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. Journal of Clinical Oncology [Internet]. 2016 Jul 10;34(20):2333–40.

Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia [Internet]. 2021 Jan 7;35(2):440–53.

Brümmendorf TH, Cortes JE, Milojkovic D, Gambacorti-Passerini C, Clark RE, le Coutre P, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia. 2022 May 28;36(7):1825–33.

Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. American Journal of Hematology. 2016 Jun 20;91(9):869–74.

Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2012 Jul 5;27(1):107–12.

Brümmendorf TH, Cortes JE, Goh YT, Yilmaz M, Klisovic RB, Purcell S, et al. Bosutinib (BOS) for chronic phase (CP) chronic myeloid leukemia (CML) after imatinib (IMA) failure: ≥8-y update of a phase I/II study. Journal of Clinical Oncology. 2020 May 20;38(15_suppl):7549–9.

Hehlmann R, Cortes JE, Zyczynski T, Gambacorti-Passerini C, Goldberg SL, Mauro MJ, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. American Journal of Hematology. 2018 Oct 31;94(1):46–54.

Massimo Breccia, Pier Paolo Olimpieri, Odoardo Olimpieri, Pane F, Iurlo A, Paolo Foggi, et al. How many chronic myeloid leukemia patients who started a frontline second‐generation tyrosine kinase inhibitor have to switch to a second‐line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer medicine. 2020 Apr 22;9(12):4160–5.

Ma CE, Ghosh S, Leyshon C, Blosser N, Deonne Dersch-Mills, Jupp J, et al. Clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI. Leukemia research. 2021 Dec 1;111:106674–4.

Claudiani S, Chughtai F, Khan A, Hayden C, Fernando F, Khorashad J, et al. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance. Leukemia [Internet]. 2024 Apr 1 [cited 2024 Apr 15];38(4):796–802.

Hochhaus A, Breccia M, Saglio G, García-Gutiérrez V, Réa D, Janssen J, et al. Expert opinion—management of chronic myeloid leukemia after resistance tosecond-generation tyrosine kinase inhibitors. Leukemia [Internet]. 2020 May 4;1–8.

Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, et al. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia. 2020 Jun 22;34(8):2125–37.

Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial. Blood [Internet]. 2018 Jul 26;132(4):393–404.

Cortes J, Apperley J, Lomaia E, Moiraghi B, Undurraga Sutton M, Pavlovsky C, et al. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood [Internet]. 2021 Nov 25;138(21):2042–50.

Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, et al. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. Blood [Internet]. 2021 Aug 20;138(21).

Hughes TP, Naranie Shanmuganathan. Management of TKI-resistant chronic phase CML. 2022 Dec 9;2022(1):129–37.

Cortes JE, Hughes TP, Mauro MJ, Hochhaus A, Rea D, Goh YT, et al. Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Blood [Internet]. 2020 Nov 5 [cited 2023 Feb 17];136(Supplement 1):47–50.

Uhm J. Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation. Blood research. 2023 Apr 30;58(S1):S109–13.

Published

2024-06-27

How to Cite

1.
Bilston L, Jamani K. Management of Chronic Myeloid Leukemia that is Intolerant or Resistant to Front-Line Treatment. Can Hematol Today [Internet]. 2024 Jun. 27 [cited 2024 Jul. 23];3(2):31–39. Available from: https://canadianhematologytoday.com/article/view/3-2-Bilston_et_al

Issue

Section

Articles